We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05195892
Recruitment Status : Completed
First Posted : January 19, 2022
Last Update Posted : December 28, 2022
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to assess bioequivalence of the granule formulation of alpelisib as compared to the film-coated tablet formulation in healthy volunteers in the fed state. In addition, the food effect of the granule formulation will be investigated between the fed state and the fasted state.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Treatment A Drug: Treatment B Drug: Treatment C Phase 1

Detailed Description:

This is a single-center, randomized, open-label, three-period six-sequence crossover study.

The study consists of a screening period followed by Periods 1, 2, and 3 and a safety follow-up. Randomization occurs at the beginning of Period 1, whereby every participant who passes the screening will be randomized to one of 6 sequences with 1:1:1:1:1:1 randomization ratio. Each sequence consists of a permutation of three treatments: A, B and C. The order of the sequence of the treatments (A, B, C) will be determined by randomization to the assigned sequence.

A total of 60 participants will be enrolled with approximately 10 participants per sequence, in order to obtain at least 48 evaluable participants for comparison of the granule formulation in fed status and the film-coated tablet formulation in fed status.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-center, Randomized, Open-label, Three-period Crossover Study to Investigate the Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation, and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers
Actual Study Start Date : February 3, 2022
Actual Primary Completion Date : November 9, 2022
Actual Study Completion Date : November 9, 2022
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Sequence 1
Participants will receive a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 2 and a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 3.
 Drug: Treatment A
Single oral dose of alpelisib film-coated tablet at 50 mg in fed state

Drug: Treatment B
Single oral dose of alpelisib granule at 50 mg in fed state

Drug: Treatment C
Single oral dose of alpelisib granule at 50 mg in fasted state
Experimental: Sequence 2
Participants will receive a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 2 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 3.
 Drug: Treatment A
Single oral dose of alpelisib film-coated tablet at 50 mg in fed state

Drug: Treatment B
Single oral dose of alpelisib granule at 50 mg in fed state

Drug: Treatment C
Single oral dose of alpelisib granule at 50 mg in fasted state
Experimental: Sequence 3
Participants will receive a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 1 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 3.
 Drug: Treatment A
Single oral dose of alpelisib film-coated tablet at 50 mg in fed state

Drug: Treatment B
Single oral dose of alpelisib granule at 50 mg in fed state

Drug: Treatment C
Single oral dose of alpelisib granule at 50 mg in fasted state
Experimental: Sequence 4
Participants will receive a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 2 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A).
 Drug: Treatment A
Single oral dose of alpelisib film-coated tablet at 50 mg in fed state

Drug: Treatment B
Single oral dose of alpelisib granule at 50 mg in fed state

Drug: Treatment C
Single oral dose of alpelisib granule at 50 mg in fasted state
Experimental: Sequence 5
Participants will receive a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B).
 Drug: Treatment A
Single oral dose of alpelisib film-coated tablet at 50 mg in fed state

Drug: Treatment B
Single oral dose of alpelisib granule at 50 mg in fed state

Drug: Treatment C
Single oral dose of alpelisib granule at 50 mg in fasted state
Experimental: Sequence 6
Participants will receive a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 1 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C).
 Drug: Treatment A
Single oral dose of alpelisib film-coated tablet at 50 mg in fed state

Drug: Treatment B
Single oral dose of alpelisib granule at 50 mg in fed state

Drug: Treatment C
Single oral dose of alpelisib granule at 50 mg in fasted state


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Maximum concentration (Cmax) of alpelisib for Treatment A and Treatment B [ Time Frame: Period 1, 2 and 3 at pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12. 24, 48, 72 and 96 hours post-dose ]
    Blood samples will be collected at specified time points to compare Cmax of the test formulation (Treatment B: granule formulation in fed state) versus the reference formulation (Treatment A: the film-coated tablet formulation in fed state). PK parameters will be calculated using noncompartmental data analysis of plasma concentration-time data


Secondary Outcome Measures :
  1. Maximum concentration (Cmax) of alpelisib for Treatment B and Treatment C [ Time Frame: Period 1, 2 and 3 at pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12. 24, 48, 72 and 96 hours post-dose ]
    Blood samples will be collected at specified time points to compare Cmax of the granule formulation in the fed state (Treatment B) versus the granule formulation in the fasted state (Treatment C). PK parameters will be calculated using noncompartmental data analysis of plasma concentration-time data.

  2. Area under plasma concentration time curve (AUC) from zero to 96 hours post dose of alpelisib for Treatment A, Treatment B and Treatment C [ Time Frame: Period 1, 2 and 3 at pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12. 24, 48, 72 and 96 hours post-dose ]
    Blood samples will be collected at specified time points to calculate AUC0-96 of alpelisib after a single oral dose of alpelisib film coated tablet formulation in fed state (Treatment A), after a single oral dose of alpelisib granule formulation in fed state (Treatment B), after a single oral dose of alpelisib granule formulation in fasted state (Treatment C). PK parameters will be calculated using noncompartmental data analysis of plasma concentration-time data


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female participants 18 and 55 years of age
  • Female participants must be postmenopausal or not of child bearing potential.
  • Participants must weigh 50 kg - 120 kg and have BMI= 18.0-30.0 kg/m2
  • Participants should be in good health as determined by no clinically significant findings from the medical history, physical examination, vital signs, and ECG.
  • Participant must have laboratory values (including fasting plasma glucose and HgbA1C) within the reference range at the local laboratory
  • At screening, and at baseline visit of each Period, participant has vital signs which are within the protocol defined ranges

Exclusion Criteria:

  • Women of childbearing potential
  • Sexually active male participant with partner(s) of women of childbearing potential, UNLESS agree to comply with highly effective contraception AND use a condom
  • Participant with
  • significant illness, including infections, or hospitalization within the 30 days prior to dosing.
  • diabetes mellitus or participants with fasting plasma glucose (FPG) levels > 100 mg/dL or >5.55 mmol/L.
  • clinically significant risk of developing diabetes mellitus during the study
  • Use of:
  • tobacco products within 3 months prior to first dosing
  • drug or alcohol abuse within 12 months prior to first dose
  • alcohol within 48 hours prior to the dosing of each treatment period.
  • any prescription or non-prescription, herbal medication, dietary supplements or vitamins during 14 days prior to dosing..
  • History of :
  • clinically significant hematologic, renal, endocrinologic, pulmonary, cardiovascular, hepatic, or allergic disease, medically documented. including uncontrolled hypertension, interstitial lung disease, or other causes of dyspnea, acute pancreatitis within 1 year of screening or past medical
  • chronic pancreatitis.
  • cardiac disease
  • immunodeficiency diseases
  • malignancy of any organ system carcinoma of the skin or in situ cervical cancer), within 5 years,
  • erythema multiform (EM), Steven-Johnson-Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).
  • history or presence of
  • any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs.
  • clinically significant ECG abnormalities or a family prolonged QT-interval syndrome.
  • chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV).

Other inclusion/exclusion criteria may apply

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05195892


Locations
Layout table for location information
United Kingdom
Novartis Investigative Site
Belfast, Northern Ireland, United Kingdom, BT9 6AD
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT05195892    
Other Study ID Numbers: CBYL719F12101
First Posted: January 19, 2022    Key Record Dates
Last Update Posted: December 28, 2022
Last Verified: December 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
adult
bioequivalence
food effect
 three-period six sequence crossover
alpelisib
BYL719